ClinicalTrials.gg

Program

SHR-2524

A development code. Also written as “SHR-2524 Injection”.

Its studies are mostly in Carcinoma, Hepatocellular, led by Jiangsu HengRui Medicine.

Furthest: phase 1, since Mar 12, 20261 company-led study, 1 open or runningNext primary completion: Oct 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jiangsu HengRui Medicine11 open or runningphase 1since Mar 12, 2026Mar 12, 2026Oct 2027phase 1 · NCT07478302
  • Named in Jiangsu HengRui Medicine’s own pipeline as SHR-2524, phase 1, as of Jul 31, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 12, 2026First study: phase 1 study in Advanced Unresectable Hepatocellular CarcinomaFirst studyNCT07478302 · 36 planned · China

Ahead

  1. Oct 2027Primary completion: phase 1 study in Advanced Unresectable Hepatocellular CarcinomaNCT07478302

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07478302Advanced Unresectable Hepatocellular Carcinoma · China1RecruitingOct 202736

How it is read

Names in the registry

  • “SHR-2524 Injection”, 1 entry

Codes read as this program: SHR2524.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.